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Introduction: Lung cancer screening using low-dose computed 
tomography (LDCT) is now widely recommended for adults who 
are current or former heavy smokers. It is important to evaluate the 
impact of screening on patient-centered outcomes. Among current 
and former smokers eligible for lung cancer screening, we sought 
to determine the consequences of screening with LDCT, and subse-
quent results, on patient-centered outcomes such as quality of life, 
distress, and anxiety.
Methods: We searched the Cochrane Central Register of Controlled 
Trials and Cochrane Database of Systematic Reviews (through the 
fourth Quarter 2012), MEDLINE (2000 to May 31, 2013), reference 
lists of articles, and Scopus for relevant English-language studies 
and systematic reviews. To evaluate the effect of LDCT screening on 
patient-centered outcomes, we included only randomized controlled 
trials (RCTs) involving asymptomatic adults. To evaluate the asso-
ciation of particular results and/or recommendations from a screen-
ing LDCT with patient-centered outcomes, we included results from 
RCTs as well as from cohort studies.
Results: A total of 8215 abstracts were reviewed. Five publications 
from two European RCTs and one publication from a cohort study 
conducted in the United States met inclusion criteria. The process of 
LDCT lung cancer screening was associated with short-term psycho-
logic discomfort in many people but did not affect distress, worry, or 
health-related quality of life. False-positive results were associated 
with short-term increases in distress that returned to levels that were 
similar to those among people with negative results. Negative results 
were associated with short-term decreases in distress.
Conclusions: As lung cancer screening is implemented in the 
general population, it will be important to evaluate its association 
with patient-centered outcomes. People considering lung cancer 
screening should be aware of the possibility of distress caused by 
false-positive results. Clinicians may want to consider tailoring 
communication strategies that can decrease the distress associated 
with these results.
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(J Thorac Oncol. 2014;9: 927–934)
It is now widely recommended to consider lung cancer screening using low-dose computed tomography (LDCT) 
for middle-aged to elderly adults with a history of substan-
tial cigarette smoking.1–6 These recommendations are largely 
based on the National Lung Screening Trial which showed 
that three annual LDCT screens decreased lung cancer mor-
tality by 20% and overall mortality by 7%.7
LDCT is associated with harms as well.8,9 The most 
direct harm to individuals stems from the high rate of false-
positive LDCT screens. In the National Lung Screening Trial, 
39% of subjects received at least one positive test, 96% of 
which were falsely positive. Individuals with false-positive 
results may experience distress as a result of a “near-cancer” 
diagnosis. Other harms, such as the potential for overdiagno-
sis and increased risk of radiation-induced cancer, are impor-
tant as well although are difficult to quantify for individual 
patients.9,10
We were particularly interested in understanding the 
influence of LDCT screening on patient-centered outcomes 
such as distress, anxiety, and quality of life (QOL). As part 
of a larger review of the benefits and harms of lung cancer 
screening conducted for the U.S. Preventive Service Task 
Force (USPSTF),9 we conducted a systematic review of evi-
dence that evaluated patient-centered outcomes for people 
who underwent screening and those who did not, and the 
association of specific LDCT screening findings with these 
outcomes.
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MATERIALS AND METHODS
A standard protocol was developed for this review. A 
technical report details the methods and includes search strat-
egies and additional evidence tables.11 Key questions address-
ing the benefits and harms of screening for lung cancer with 
LDCT were developed by the USPSTF with input from scien-
tific staff at the Agency for Healthcare Research and Quality.11 
This report focuses on the association of LDCT lung cancer 
screening with patient-centered outcomes. Investigators cre-
ated an analytic framework incorporating the key questions 
and outlining the patient populations, interventions, outcomes, 
and harms of LDCT screening for lung cancer. The Preferred 
Reporting Items for Systematic Reviews and Meta-analyses 
consensus was followed for the systematic review.12
Data Sources and Searches
In conjunction with a research librarian, investigators 
searched the Cochrane Central Register of Controlled Trials 
and Cochrane Database of Systematic Reviews (through the 
fourth Quarter 2012), MEDLINE (2000 to May 31, 2013), 
reference lists of articles, and Scopus for relevant English-
language studies and systematic reviews. These dates overlap 
with those of the previous review of the effectiveness of lung 
cancer screening.13
Study Selection
Each abstract was initially reviewed by one investigator, 
and if possibly relevant to the key question, then independently 
reviewed by two investigators to determine eligibility for inclu-
sion. To evaluate the effect of LDCT screening on patient-cen-
tered outcomes, we included only randomized controlled trials 
(RCTs) involving asymptomatic adults at high risk of lung 
cancer because of smoking behaviors that compared screen-
ing with no screening. To evaluate the association of specific 
results and/or recommendations from a screening LDCT with 
patient-centered outcomes, we included results from RCTs and 
cohort studies that involved asymptomatic adults at high risk 
of lung cancer because of smoking behaviors.
Data Extraction and Quality Assessment
For each included study, one investigator abstracted 
details about the patient population, study design, screening pro-
cedure, LDCT findings, and patient-centered outcomes which 
were confirmed by a second investigator. By using predefined 
criteria for RCTs and cohort studies developed by the USPSTF,14 
two investigators rated the quality of studies (good, fair, or poor) 
and resolved discrepancies by consensus. We assessed the over-
all quality of the body of evidence (good, fair, or poor) using 
methods developed by the USPSTF on the basis of the number, 
quality, and size of studies; consistency of results; and directness 
of evidence.14,15 When studies reported findings in more than one 
article, data from the most recent publication were used unless 
unique data were presented in a previous publication.
Data Synthesis and Analysis
Values and ranges for summary statistics are reported 
based on information provided by the study authors. Trial 
results could not be meaningfully combined because of het-
erogeneity of the outcome measures.
External Review
The draft report, from which the current analysis is 
based, was reviewed by content experts, USPSTF members, 
Agency for Healthcare Research and Quality Project Officers, 
and collaborative partners.11
RESULTS
A total of 8215 abstracts were reviewed. Five publica-
tions from two RCTs16–20 and one publication from a cohort 
study21 were included (Fig. 1). In general, the quality of these 
studies was fair. Table 1 includes details about the screening 
studies. Quality ratings are reported in Supplementary Tables 
1 and 2 (Supplementary Digital Content, http://links.lww.
com/JTO/A624).
Influence of LDCT Screening
Two reports each from the Danish Lung Cancer 
Screening Trial (DLCST) and the Nederlands-Leuvens 
Longkanker Screenings Onderzoek (NELSON) study evalu-
ated patient-centered outcomes.16–18,20 The DLCST compared 
LDCT with no screening22 and enrolled healthy men and 
women with ages 50 to 70 years, who were current or for-
mer (quit after age 50 and <10 years prior) smokers with 
20 pack-years or greater smoking history.22 All subjects 
were administered the Consequences of Screening (COS) 
scale (includes items on anxiety, negative impact on behav-
ior, dejection, and sleep) and Consequences of Screening in 
Lung Cancer (COS-LC) scale (includes items on self-blame, 
focus on airway symptoms, stigmatization, introvert, harm 
of smoking, and anxiety)23 at two time points: before ran-
domization and at the time of the second LDCT.16 Subjects 
with positive LDCT results for lung cancer (including false 
positives) were excluded. Before randomization, there were 
no differences in the COS scores between screen and control 
subjects. More subjects in the control arm did not complete 
the second survey compared with LDCT subjects (92% ver-
sus 97%). Control subjects at baseline had worse scores in 
the anxiety, behavior, dejection, self-blame, focus on symp-
toms, and introvert domains of the COS and COS-LC sur-
veys. Subjects in both arms reported statistically significant 
increases in several scales, including the negative impact 
on behavior, dejection, and sleep scales, but the degree of 
change was similar in both groups. This study did not report 
on the minimally important difference (the smallest change 
that a patient would consider as significant) of the COS or 
COS-LC scales or domains (Table 2).
DLCST investigators also examined the new prescrip-
tion of antidepressant and anxiolytic medications as recorded 
in the Danish National Prescription Registry among all con-
trol and LDCT subjects.17 Subjects were followed for up to 3 
years after randomization and censored from analysis if they 
died, emigrated, or were diagnosed with lung cancer. No dif-
ferences were found between the screen or control group in 
terms of prescriptions for antidepressant or anxiolytic medi-
cations (hazard ratio, 1.00; 95% confidence interval [CI], 
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0.90–1.12), even when adjusted for important confounders 
such as age, sex, and previous prescription of antidepressant 
and anxiolytic medications.
Several reports from the NELSON trial, which com-
pares LDCT with no screening,24 described patient-centered 
outcomes (Table 2). NELSON is being conducted in The 
Netherlands and Belgium, enrolling male and female former 
and current smokers (≥15 cigarettes per day for >25 years, or 
>10 cigarettes per day for >30 years, and if a former smoker, 
quit ≤10 years before enrollment), ages 50 to 75 years.
Final included papers‡: 67
Abstracts of potentially relevant papers identified through MEDLINE, 
Cochrane*, and other sources† (N = 8215)
Excluded abstracts (n = 6474)
Full-text papers reviewed for relevance to 
Key Question (n = 1741) 
Excluded full-text papers (n  = 1674) 
Background = 403
Wrong population = 117
Wrong intervention = 146
Wrong publication type = 539
Non-English = 304
Wrong outcome = 98
Published prior to 2000 = 22
Sample size too small =44
Follow-up too short =1
Screening key questions:
54
Treatment key questions: 
13
RCTs(n = 31)
DANTE: 2
DLCST: 5
ITALUNG: 3
LSS: 4
MILD: 1
NELSON: 9
NLST: 3
PLCO: 3
LUSI: 1
Cohort studies (n = 23)
COSMOS: 3
I-ELCAP: 9
Mayo: 5
PALCAD: 1
PLUSS: 3
Japanese population: 2
Cohort studies (n = 13)
Evaluated patient-
centered outcomes  
(n=5)
DLCST: 2
NELSON: 3
Evaluated patient-
centered outcomes (n=1)
PLUSS: 1
FIGURE 1.  Selection of studies. *Cochrane 
databases include the Cochrane Central 
Register of Controlled Trials and the 
Cochrane Database of Systematic Reviews. 
†Identified from reference lists, hand 
searching, suggested by experts, etc. 
‡Studies that provided data and con-
tributed to the body of evidence were 
considered “included.” RCT, random-
ized controlled trial; DANTE, Detection 
and Screening of Early Lung Cancer by 
Novel Imaging Technology and Molecular 
Essays; DLCST, Danish Lung Cancer 
Screening Trial; I-ELCAP, International 
Early Lung Cancer Action Program; 
LSS, Lung Screening Study; LUSI, Lung 
Cancer Screening Intervention; MILD, 
Multicentric Italian Lung Detection; 
NELSON, Dutch -Belgian Randomised 
Controlled Trial for Lung Cancer Screening 
in High-Risk Subjects; NLST, National Lung 
Screening Trial; PALCAD, ProActive Lung 
Cancer Detection; PLCO, Prostate, Lung, 
Colorectal, and Ovarian; PLuSS, Pittsburgh 
Lung Screening Study.
TABLE 1.  Summary of Included Studies (n = 4)
Study, Recruitment Years Population/Eligibility
No. of Screening 
Rounds Psychosocial Outcome (Instrument)
Randomized controlled trials
  DLCST,16,17
2004–2006
•  Age: 50–70 yr
•  Current or former smokers (quit after age 
50 and younger than 10 years prior)
•  ≥20 pack-years
•  5 •  Anxiety, sense of dejection, negative impact on 
behavior and sleep, busy to take mind of things, 
less interest in sex (COS, COS-LC)
•  Focus on airway symptoms, introvert, stigmatization, 
harm of smoking, self-blame (COS-LC)
•  Redeemed AD or AX prescriptions
  NELSON,18–20
First phase: 2003 to NR
Second phase: October 2005 to NR
•  Age: 50–75 years
•  Current smokers or former smokers  
(≤10 years prior)
•  >15 cigarettes per day for >25 years  
or >10 cigarettes per day for >30 years
•  3 •  Health-related quality of life (EQ-5D, SF-12)
•  Anxiety (STAI-6)
•  Distress (IES)
Cohort
  PLuSS,21
January 2002 to April 2005
•  Age: 50–79 years
•  Current smokers or former smokers  
(≤10 years prior)
•  ≥1/2 pack per day for ≥25 years
• 2 • Anxiety (STAI)
• Fear (PCQ)
AD, antidepressant; AX, anxiolytic; COS-LC, Consequences of Screening in Lung Cancer; DLCST, Danish Lung Cancer Screening Trial; EQ-5D, EuroQol questionnaire; IES, 
Impact of Event Scale; NELSON, NEderlands Leuvens Longkanker Screenings Onderzoek; NR, not reported; PCQ, Psychological Consequences Questionnaire; PLuSS, Pittsburgh 
Lung Screening Study; SF-12, 12-item Short Form; STAI, Full version Spielberger State-Trait Anxiety Inventory; STAI-6, Six-item Spielberger State-Trait Anxiety Inventory.
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One report included a subset of 351 subjects consecu-
tively randomized to the LDCT arm who were asked to com-
plete surveys that assessed discomfort, health-related quality 
of life (HRQOL) (12-item Short Form [SF-12] and EuroQOL 
questionnaire [EQ-5D]), anxiety (6-item State-Trait Anxiety 
Inventory [STAI-6]), and lung cancer–specific distress 
(Impact of Event Scale [IES]) after the LDCT.18 These surveys 
were completed 1 week before the LDCT, 1 week afterward 
(before receiving results), and 6 months afterward. Subjects 
with positive results, those with growth of a suspicious lesion 
noted at the time of a repeat scan, those with indeterminate 
results at baseline without being informed of repeat results, 
and those who did not receive the initial LDCT or refused 
subsequent questionnaires were excluded. The response rate 
for each questionnaire was more than 90%, and 77% returned 
all three. Many participants reported discomfort in connection 
with having to wait for the results of the computed tomography 
(CT) scan (46%) and dreading those results (50%). In general, 
the median HRQOL, anxiety, and distress scores did not seem 
to change more than the minimally important difference over 
time. Compared with respondents who did not report discom-
fort waiting for CT results, those reporting discomfort had 
worse anxiety and distress scores (p < 0.01) which exceeded 
the minimally important difference at all three assessments.
NELSON investigators also evaluated differences 
between screened and control subjects. An initial sample of 
1466 subjects from both arms was surveyed at three time 
intervals: before randomization, 2 months after baseline 
screening (screen group only), and at 2-year follow-up.20 They 
evaluated HRQOL (SF-12, EQ-5D), anxiety (STAI-6), lung 
cancer–specific distress (IES). Response rates were more than 
85% for each survey except for the 2-year survey sent to the 
control subjects which had a 65% response rate. Between the 
baseline and 2-year follow-up surveys, there were no signifi-
cant differences in any psychosocial outcome scores between 
the screen and control groups.
Influence of LDCT Result
Two reports from NELSON included information 
on the association of LDCT findings and patient-centered 
 outcomes (Table 3). Several outcomes, including HRQOL 
(SF-12, EQ-5D), anxiety (STAI-6), lung cancer–specific dis-
tress (IES), were measured at four time intervals: before ran-
domization, 1 week before the LDCT, within 1 day after the 
LDCT (before result), and 2 months after the LDCT (before 
the 3-month follow-up CT for patients with indeterminate 
results).19 This study included most of the same subjects as 
reported in the report from NELSON that evaluated long-term 
outcomes among screened and control patients.20 Response to 
each questionnaire was 88% or higher and 71% returned all 
four questionnaires. Scores on the HRQOL and anxiety instru-
ments showed no clinically relevant changes over time. At 2 
months after baseline, distress scores significantly increased 
more than the minimally important difference after an inde-
terminate result, whereas these scores showed a significant 
decrease after a negative result. Differences in distress scores 
between indeterminate and negative result groups were both 
significant and more than the minimally important difference 
(p < 0.01) at 2 months after baseline.
This group also reported on long-term associations with 
LDCT findings.20 There was a temporary increase in mean 
distress scores after an indeterminate LDCT result (4.0 [95% 
CI, 2.8–5.3] before randomization, 7.8 [95% CI, 6.5–9.0] 2 
months after baseline LDCT, and 4.5 [95% CI, 3.3–5.8] 2 
years after baseline LDCT). Participants with negative results 
had decreases in mean distress scores at 2 months after the 
baseline LDCT (4.1 [95% CI, 3.4–4.8], 2.6 [95% CI, 2.0–3.3], 
and 3.5 [95% CI, 2.9–4.2] at the same time points). Between 
groups, these differences were more than the minimally impor-
tant difference and statistically significant at the 2-month sur-
vey (p < 0.01). At the 2-year follow-up survey, distress scores 
between groups were no longer significantly different. Other 
statistically significant differences in outcome scores were not 
more than the minimally important difference.
We included one cohort study. Among a subset of sub-
jects in the Pittsburgh Lung Screening Study (PLuSS), the 
authors evaluated state/trait anxiety, fear of cancer, and per-
ceived risk of lung cancer over time (before initial screening, 
1–2 weeks after the result, 6 months after baseline screen, 
and 12 months after the baseline screen).21 The PLuSS was 
conducted in the United States and enrolled 3642 men and 
women ages 50 to 79 years who were current or former smok-
ers with at least one half pack per day for 25 years and had 
quit less than 10 years before enrollment. Overall, subjects 
with negative results had no change in anxiety (Table 3). For 
subjects with indeterminate or suspicious results, state anxiety 
increased 1 to 2 weeks after the result was known and then 
decreased to baseline at 1 year.
DISCUSSION
In summary, we found six studies of fair quality that 
evaluated psychosocial consequences among individuals 
undergoing LDCT screening. In European trials, screening 
did not seem to significantly affect overall HRQOL, and no 
long-term differences in anxiety or distress were reported. In 
the short term, the studies suggested that participants with 
positive or indeterminate results for lung cancer had increased 
distress compared with their baseline level, whereas those 
with negative results often had decreased distress. Overall 
HRQOL and anxiety did not seem to substantially change 
over time or differ in association with LDCT results. Over the 
long-term, distress seemed to be similar for participants with 
both indeterminate and negative results. In general, it appears 
distress increases after a positive result and then returns to 
similar levels to those with negative results.
Similar to our findings, a systematic review of patients 
with false-positive mammograms found that increased worry 
was the most common consequence.25 In general, however, 
there is a paucity of data regarding the association of cancer 
screening procedures with patient-centered outcomes.26 It is 
also important to consider how distress and worry from lung 
cancer screening might lead to other adverse outcomes such 
as nonadherence to recommendations and negative health 
behaviors, as postulated by the Biobehavioral Model of 
Cancer Stress.27
Although it is important to quantify adverse outcomes 
that are associated with the lung cancer screening process, 
933Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 7, July 2014 Patient-Centered Outcomes
it is unknown whether these consequences can be modified 
or are intrinsically linked to unalterable aspects of the pro-
cess. Given the high rate of false-positive results7 from LDCT 
screening and the evidence that distress is associated with 
these results, strategies that decrease the risk for a positive 
result may be important. Careful consideration of eligibility 
criteria,28,29 optimizing the balance of sensitivity versus speci-
ficity of LDCT result reporting,30 and following diagnostic 
algorithms31 are potential interventions.
As false-positive results will never be eliminated, opti-
mizing communication processes, such as discussions of risk, 
benefits, values, and preferences, notification of the result 
and its implications, and follow-up plans, may also improve 
patient-centered outcomes.32 Communication is a cornerstone 
of the patient–clinician relationship and is a critical compo-
nent of high-quality, patient-centered care.33 The Institute 
of Medicine and the National Cancer Institute emphasize 
the importance of improving communication strategies as a 
means of improving patient outcomes.34,35 Improving patient 
and clinician knowledge is a core domain of patient-centered 
communication36 and it is recommended that information 
exchange focus on plain language, describe absolute instead 
of relative risks, and include tables and graphs.37 However, 
a report from the NELSON study found that participant’s 
knowledge about screening, which was in general higher than 
nonparticipants,38 was not associated with patient-centered 
outcomes.39 Thus, attention to additional elements of quality 
communication, such as shared decision making and consid-
ering the patient’s values and preferences, may be important.
As LDCT screening is incorporated into general prac-
tice, it will be important to continue to evaluate its influence 
on patient-centered outcomes (Tables 2 and 3). Volunteers in 
screening trials have different demographic and socioeco-
nomic characteristics than otherwise screening-eligible people 
in the general population.40 Results from the DLCST showed 
that eligible nonparticipants had more negative psychosocial 
characteristics than participants, even after adjustment for 
important sociodemographic characteristics.41 Finally, proce-
dures for communication of results differ in screening trials 
compared with routine practice. Notably, studies from two 
cohorts of patients in the United States with incidental pulmo-
nary nodules found that many of these patients also appeared 
to experience distress.42–44
Although not the focus of our review, several of the 
included studies reported findings that suggested certain 
demographic and behavioral characteristics were associ-
ated with patient-centered outcomes. For instance, in the 
NELSON study, levels of HRQOL were worse for women, 
current smokers, and subjects with more pack-years of smok-
ing.19,20 Subjects with higher perceived risk of lung cancer 
also reported higher levels of distress.45 In the PLuSS, cur-
rent smokers had higher levels of anxiety, fear of cancer and 
perceived risk of cancer, women reported higher levels of fear 
of cancer, and married participants and those in higher edu-
cation classes had lower anxiety levels.21 Efforts to improve 
patient-centered outcomes should consider focused efforts 
among these categories of patients at higher risk for negative 
outcomes.
Our review and the results have several limitations. 
Despite identifying more than 8000 articles in our search, we 
may have missed relevant results. Most of the results come 
from European screening trials so it is unclear how gener-
alizable these results will be to people in the United States 
who undergo screening as part of routine care. In addition, 
we found patient-centered outcomes were reported from only 
four of 20 screening studies that were included in our related 
review that focused on mortality and other outcomes.9 Finally, 
we did not find evidence regarding how people view the trad-
eoffs between the potential mortality benefit and risks of harm 
that are engendered from lung cancer screening.
In conclusion, limited, fair-quality evidence suggests 
that lung cancer screening with LDCT was associated with 
short-term psychologic discomfort in many people but 
does not impact distress, worry, or HRQOL. False-positive 
results are associated with short-term increases in distress 
that return to levels that are similar to those among peo-
ple with negative results. Negative results are associated 
with short-term decreases in distress. In lieu of evidence 
regarding how to improve patient-centered outcomes among 
screened people, clinicians may want to focus on decreas-
ing the chance of false-positive results and optimize com-
munication strategies that emphasize adequate information 
exchange, consideration of values and preferences, and 
shared decision making.
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